Free Trial

Guardant Health (NASDAQ:GH) Upgraded to "Strong-Buy" at Evercore ISI

Guardant Health logo with Medical background

Guardant Health (NASDAQ:GH - Get Free Report) was upgraded by analysts at Evercore ISI to a "strong-buy" rating in a report released on Monday,Zacks.com reports.

GH has been the subject of a number of other reports. Stephens restated an "overweight" rating and set a $55.00 price objective on shares of Guardant Health in a research note on Wednesday, March 26th. Canaccord Genuity Group raised their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Mizuho lifted their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Friday, June 13th. UBS Group lifted their price target on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Finally, Barclays lifted their price target on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $53.76.

Get Our Latest Stock Analysis on GH

Guardant Health Stock Performance

Shares of GH stock traded down $0.45 on Monday, hitting $46.83. 285,740 shares of the company's stock traded hands, compared to its average volume of 2,167,181. The stock has a market capitalization of $5.80 billion, a price-to-earnings ratio of -13.83 and a beta of 1.44. The company's fifty day simple moving average is $46.21 and its 200 day simple moving average is $44.17. Guardant Health has a one year low of $20.14 and a one year high of $53.42.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. The firm had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. During the same period in the previous year, the company earned ($0.46) EPS. The company's quarterly revenue was up 20.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Ian T. Clark sold 6,672 shares of the stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the sale, the director directly owned 9,851 shares of the company's stock, valued at approximately $476,591.38. This represents a 40.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Meghan V. Joyce sold 3,337 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $47.22, for a total transaction of $157,573.14. Following the completion of the transaction, the director directly owned 11,150 shares of the company's stock, valued at $526,503. The trade was a 23.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 342,158 shares of company stock valued at $17,075,394. Company insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC raised its holdings in Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company's stock valued at $33,000 after buying an additional 213 shares during the period. SVB Wealth LLC acquired a new position in Guardant Health in the 1st quarter valued at about $54,000. NewEdge Advisors LLC grew its position in shares of Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Guardant Health during the fourth quarter worth about $61,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Guardant Health in the first quarter valued at approximately $97,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Guardant Health Company Profile

(Get Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Stories

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Should You Invest $1,000 in Guardant Health Right Now?

Before you consider Guardant Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.

While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential
Time to Cash Out? 5 Stocks to Drop Before Earnings

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines